Continuous Ketone Sensing to Prevent DKA
Diabetic ketoacidosis is a costly and potentially deadly complication for people
with diabetes that can be identified and prevented with ketone detection.
Integrating continuous ketone monitoring with glucose sensing is a unique opportunity to
improve on existing CGM technology. The ability to continuously monitor ketone levels,
in addition to glucose, is in high demand for endocrinologists and patients.
200,000
hospitalizations
annually for DKA
in U.S. alone
$5.1
billion
total cost of DKA hospitalizations
in the U.S.
620
deaths
in the U.S. from DKA
SGLT inhibitors benefit T1Ds but at the risk of increased DKA.
With active ketone monitoring, the benefits of SGLT inhibitors outweigh the risks for T1Ds. Continuous ketone monitoring will help enable a new class of oral medications benefiting people with Type 1 Diabetes.
SGLT Inhibitor Benefits
Weight
reduction
Lower A1C
with no increase
in hypoglycemia
Potentially
cardio and renal protective
SGLT Inhibitor Risks
7x
increase in DKA incidence in SGLT2 inhibitor studies in T1Ds
The PercuSense Solution
PercuSense’s solution provides built in ketone monitoring with its glucose sensor. Measuring both analytes on a single probe, the system measures ketones levels without any added burden to the user. The ketone sensor will provide an early warning of DKA risk to prompt user action.
